Patients’ baseline demographic and disease characteristics (N = 270)
| Parameter . | Value . |
|---|---|
| Age, median (IQR), y | 63 (53-71) |
| Female sex, N (%) | 137 (51.5) |
| Previous symptomatic COVID-19 infection, N (%) | 27 (10) |
| Previous antibody response to SARS-CoV2, N (%) | 24 (8.9) |
| Previous interferon-γ–producing SARS-CoV-2–reactive T cells, N (%) | 23 (8.5) |
| Underlying disease, N (%) | |
| Lymphoid malignancies and MM cohort | 200 (74.1) |
| CLL | 52 (26) |
| Lymphoma | 85 (42.5) |
| MM | 63 (31.5) |
| allo-SCT | 70 (25.9) |
| Treatment status, N (%) | |
| Lymphoid malignancies and MM cohort | |
| Treatment-naive | 32 (16) |
| On current therapy/<6 mo | 130 (65) |
| Off therapy ≥6 mo | 38 (19) |
| allo-SCT | |
| On current therapy/<6 mo | 4 (5.7) |
| Prophylactic/therapeutic GVHD treatment | 23 (32.9) |
| Type of treatment (current and <6 mo), N (%) | |
| Lymphoid malignancies and MM cohort | |
| Chemotherapy | 8 (6.1) |
| Anti-CD20 monoclonal antibodies ± chemoimmunotherapy | 47 (36.2) |
| BTK inhibitor | 31 (23.8) |
| IMIDs | 30 (23.1) |
| Other target therapies | 14 (10.8) |
| allo-SCT | |
| Target therapies | 4 (5.7) |
| Immunosuppressive agents for GVHD | 23 (32.9) |
| Previous treatment, N (%) | |
| 1 line | 118 (59.6) |
| 2 lines | 57 (28.8) |
| ≥3 lines | 23 (11.6) |
| Disease status of patients, N (%) | |
| Complete response/partial response | 206 (86.6) |
| Stable disease/progressive disease | 32 (13.4) |
| Laboratory parameters, median (IQR) | |
| Absolute neutrophil count, 109/L | 3.8 (2.5-4.8) |
| Absolute lymphocyte count, 109/L | 1.8 (1.2-2.8) |
| IgG, mg/dL | 833 (585-1081.8) |
| IgM, mg/dL | 45 (27-85.75) |
| IgA, mg/dL | 134.5 (60-201.8) |
| Basal immunologic condition, N (%) | |
| Leukopenia (WBC <4 × 109/L) | 38 (14.1) |
| Lymphopenia (ALC <1.0 × 109/L) | 39 (14.4) |
| Neutropenia (ANC <2.0 × 109/L) | 37 (13.7) |
| Low IgG (<700 mg/dL) | 92 (34.1) |
| Low IgM (<40 mg/dL) | 120 (44.4) |
| Low IgA (< 0 mg/dL) | 78 (29.3) |
| Days between second dose of vaccine and antibody test, median (IQR) | 26 (22-28) |
| Parameter . | Value . |
|---|---|
| Age, median (IQR), y | 63 (53-71) |
| Female sex, N (%) | 137 (51.5) |
| Previous symptomatic COVID-19 infection, N (%) | 27 (10) |
| Previous antibody response to SARS-CoV2, N (%) | 24 (8.9) |
| Previous interferon-γ–producing SARS-CoV-2–reactive T cells, N (%) | 23 (8.5) |
| Underlying disease, N (%) | |
| Lymphoid malignancies and MM cohort | 200 (74.1) |
| CLL | 52 (26) |
| Lymphoma | 85 (42.5) |
| MM | 63 (31.5) |
| allo-SCT | 70 (25.9) |
| Treatment status, N (%) | |
| Lymphoid malignancies and MM cohort | |
| Treatment-naive | 32 (16) |
| On current therapy/<6 mo | 130 (65) |
| Off therapy ≥6 mo | 38 (19) |
| allo-SCT | |
| On current therapy/<6 mo | 4 (5.7) |
| Prophylactic/therapeutic GVHD treatment | 23 (32.9) |
| Type of treatment (current and <6 mo), N (%) | |
| Lymphoid malignancies and MM cohort | |
| Chemotherapy | 8 (6.1) |
| Anti-CD20 monoclonal antibodies ± chemoimmunotherapy | 47 (36.2) |
| BTK inhibitor | 31 (23.8) |
| IMIDs | 30 (23.1) |
| Other target therapies | 14 (10.8) |
| allo-SCT | |
| Target therapies | 4 (5.7) |
| Immunosuppressive agents for GVHD | 23 (32.9) |
| Previous treatment, N (%) | |
| 1 line | 118 (59.6) |
| 2 lines | 57 (28.8) |
| ≥3 lines | 23 (11.6) |
| Disease status of patients, N (%) | |
| Complete response/partial response | 206 (86.6) |
| Stable disease/progressive disease | 32 (13.4) |
| Laboratory parameters, median (IQR) | |
| Absolute neutrophil count, 109/L | 3.8 (2.5-4.8) |
| Absolute lymphocyte count, 109/L | 1.8 (1.2-2.8) |
| IgG, mg/dL | 833 (585-1081.8) |
| IgM, mg/dL | 45 (27-85.75) |
| IgA, mg/dL | 134.5 (60-201.8) |
| Basal immunologic condition, N (%) | |
| Leukopenia (WBC <4 × 109/L) | 38 (14.1) |
| Lymphopenia (ALC <1.0 × 109/L) | 39 (14.4) |
| Neutropenia (ANC <2.0 × 109/L) | 37 (13.7) |
| Low IgG (<700 mg/dL) | 92 (34.1) |
| Low IgM (<40 mg/dL) | 120 (44.4) |
| Low IgA (< 0 mg/dL) | 78 (29.3) |
| Days between second dose of vaccine and antibody test, median (IQR) | 26 (22-28) |
ALC, absolute lymphocyte count;ANC, absolute neutrophil count; WBC, white blood cell count.